Generali SpA

Welcome to the Generali Group
Please select your country

Our locations
                           

Financial calendar

March

  • 17 Mar 2016

    Financial events

    Board of Directors - Approval of consolidated financial statements and draft separate financial statements for the year to 31 December 2015

  • 18 Mar 2016

    Financial events

    Annual Results reporting 2015

April

  • 28 Apr 2016

    Financial events

    Annual General Meeting - Approval of the 2015 separate financial statements

May

  • 11 May 2016

    Financial events

    Board of Directors - Approval of the quarterly report at 31 March 2016

  • 12 May 2016

    Financial events

    First Quarter Results release

  • 23 May 2016

    Financial events

    Dividend date - Generali share ex-dividend date

  • 25 May 2016

    Financial events

    Dividend payment - Generali share dividend payment date

July

  • 28 Jul 2016

    Financial events

    Board of Directors - Approval of the half-year report at 30 June 2016

  • 29 Jul 2016

    Financial events

    First Half Results release

November

  • 09 Nov 2016

    Financial events

    Board of Directors - Approval of the interim financial information as of September 30 2016

  • 10 Nov 2016

    Financial events

    Interim financial information as of September 30 2016 release

  • 23 Nov 2016

    Financial events

    Investor Day - Update on Generali Group's strategy

The dates given above are provided purely as general indications: any changes will be promptly announced to the market, using the channels used to distribute this statement.

The dates of the meetings with the investors will be communicated once set.


Please note that the above dates are purely for information purposes. Any change will be promptly disclosed to the market and published on the website.  
The group will normally apply a closed period of four weeks before the publication of results, and before major events like Investor Days or Annual General Meetings. During this time, we will not arrange investor or analyst meetings or attend conferences. Investor & Rating Agency Relations team will remain available to respond to fact based information requests during this period.